Effect of antihypertensive agents on risk of atrial fibrillation: A meta-analysis of large-scale randomized trials

Europace

Volumn 17, Issue 5, 2015, Pages 701-710

  Emdin, Connor A ^a   Callender, Tom ^a   Cao, Jun ^a,b   Rahimi, Kazem ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Antihypertensive therapy; Atrial fibrillation; Epidemiology; Meta analysis

Indexed keywords

ANTIHYPERTENSIVE AGENT; PLACEBO;

ANTIHYPERTENSIVE THERAPY; ARTICLE; ATRIAL FIBRILLATION; CARDIOVASCULAR RISK; DATA ANALYSIS; DATA EXTRACTION; DATA SYNTHESIS; DRUG EFFECT; HUMAN; META ANALYSIS; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; AGED; BLOOD PRESSURE; COMPLICATION; DRUG EFFECTS; FEMALE; HEART FAILURE; HYPERTENSION; MALE; MIDDLE AGED; ODDS RATIO; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TREATMENT OUTCOME;

AGED; ANTIHYPERTENSIVE AGENTS; ATRIAL FIBRILLATION; BLOOD PRESSURE; FEMALE; HEART FAILURE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 84929246957     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euv021     Document Type: Article

References (49)

1. Lip GYH, Brechin CM, Lane DA. The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. Chest 2012;142:1489-98.
2. Murray CJL, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2197-223.
3. Zimetbaum P. Antiarrhythmic drug therapy for atrial fibrillation. Circulation 2012; 125:381-9.
4. Rahimi K, Emberson J, McGale P, MajoniW, Merhi A, Asselbergs FW et al. Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials. BMJ 2011;342:d1250.
5. Benjamin EJ, Levy D, Vaziri SM, DAgostino RB, Belanger AJ,Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994;271:840-4.
6. Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997;96:2455-61.
7. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005;45:1832-9.
8. Du X, Ninomiya T, de Galan B, Abadir E, Chalmers J, Pillai A et al. Risks of cardiovascular events and effectsof routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of theADVANCE study. Eur Heart J 2009;30: 1128-35.
9. ACTIVE I Investigators, Yusuf S, Healey JS, Pogue J,Chrolavicius S, Flather M, HartRG et al. Irbesartan in patients with atrial fibrillation. N Engl J Med 2011;364:928-38.
10. Nasr IA, Bouzamondo A, Hulot J-S, Dubourg O, Le Heuzey J-Y, Lechat P. Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. Eur Heart J 2007;28:457-62.
11. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gtzsche PC, Ioannidis JPA et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009;6:e1000100.
12. Law MR, Morris JK,Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665.
13. Turnbull F. Blood Pressure Lowering Treatment Trialists Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362: 1527-35.
14. Rahimi K, Bhala N, Kamphuisen P, Emberson J, Biere-Rafi S, Krane V et al. Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials. PLoS Med 2012;9:e1001310.
15. Pogue J,Walter SD, Yusuf S. Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs. Clin Trials 2009;6:239-51.
16. Lehto M, Snapinn S, Dickstein K, Swedberg K, Nieminen MS, OPTIMAAL investigators. Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience. Eur Heart J 2005;26:350-6.
17. Dargie HJ. Effect of carvedilol onoutcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357: 1385-90.
18. Haywood LJ, Ford CE, Crow RS, Davis BR, Massie BM, Einhorn PT et al. Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). J Am Coll Cardiol 2009; 54:2023-31.
19. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, SchumacherHet al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59.
20. Helgeland A. Treatment of mild hypertension: a five year controlled drug trial. The Oslo study. Am J Med 1980;69:725-32.
21. Higgins JP, Green S, (eds). Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Handbook for Systematic Reviews of Interventions. Chichester, UK: John Wiley & Sons, Ltd; 2008. pi-xxi.
22. Savelieva I, Kakouros N, Kourliouros A, Camm AJ. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. Europace 2011;13: 308-28.
23. Savelieva I, Kakouros N, Kourliouros A, Camm AJ. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. Europace 2011;13: 308-28.
24. CammAJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010;12:1360-420.
25. GISSI-AF Investigators, Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L, MaggioniAPet al. Valsartan for prevention of recurrent atrial fibrillation.NEngl J Med 2009;360:1606-17.
26. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlöf B et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention for End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005;45:712-9.
27. Marott SCW, Nielsen SF, Benn M, Nordestgaard BG. Antihypertensive treatment and risk of atrial fibrillation: a nationwide study. Eur Heart J 2014;35:1205-14.
28. SchneiderMP, Hua TA, Bohm M,Wachtell K, Kjeldsen SE, Schmieder RE. Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis. J Am Coll Cardiol 2010;55:2299-307.
29. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344: 1659-67.
30. Verdecchia P, Staessen JA, Angeli F, de Simone G, Achilli A, Ganau A et al. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet 2009;374:525-33.
31. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611-6.
32. McMurray J, Kber L, Robertson M, Dargie H, ColucciW, Lopez-Sendon J et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 2005;45:525-30.
33. Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006;152:86-92.
34. Marre M, Lievre M, Chatellier G, Mann JFE, Passa P, Menard J, DIABHYCAR Study Investigators. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ 2004;328:495.
35. Pizzetti F, Turazza FM, Franzosi MG, Barlera S, Ledda A, Maggioni AP et al. Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data. Heart 2001;86:527-32.
36. SalehianO, Healey J, Stambler B, Alnemer K, Almerri K, Grover J et al. Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study. Am Heart J 2007;154:448-53.
37. van Veldhuisen DJ, Aass H, Allaf El D, Dunselman PHJM, Gullestad L, HalinenMet al. Presence and development of atrial fibrillation in chronic heart failure. Experiences from the MERIT-HF Study. Eur J Heart Fail 2006;8:539-46.
38. Latini R, Staszewsky L, Sun JL, Bethel MA, Disertori M, Haffner SM et al. Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors.Apost hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial. Am Heart J 2013; 166:935-40. e1.
39. Hansson L, HednerT, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JOet al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000;356:359-65.
40. Packer M, Carson P, Elkayam U, Konstam MA, Moe G, OConnor C et al. Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (Prospective Randomized Amlodipine Survival Evaluation 2). JACC Heart Fail 2013;1:308-14.
41. Yusuf S, DienerHC, Sacco RL, Cotton D,Ounpuu S, LawtonWAet al.Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008;359: 1225-37.
42. Flather MD, Shibata MC, Coats AJS, van Veldhuisen DJ, Parkhomenko A, Borbola J et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215-25.
43. Vagaonescu TD, Wilson AC, Kostis JB. Atrial fibrillation and isolated systolic hypertension: the systolic hypertension in the elderly program and systolic hypertension in the elderly program-extension study. Hypertension 2008;51:1552-6.
44. Vermes E, Tardif J-C, Bourassa MG, Racine N, Levesque S, White M et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003;107:2926-31.
45. Hansson L, Lindholm LH, Ekbom T, Dahlöf B, Lanke J, Scherstén B et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751-6.
46. Kber L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, LyngborgK et al.Aclinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995;333:1670-6.
47. Telmisartan Randomised AssessmeNtStudy inACE iNtolerant subjects with cardiovascular Disease (TRANSCEND)Investigators, Yusuf S,TeoK, Anderson C, Pogue J, Dyal L, Copland I et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008;372:1174-83.
48. Maggioni AP, Latini R, Carson PE, Singh SN, Barlera S, Glazer R et al. Val-HeFT Investigators. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005; 149:548-57.
49. Schmieder RE, Kjeldsen SE, Julius S, McInnes GT, Zanchetti A, Hua TA, VALUE trial group. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens 2008;26:403-11.